UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

           March 1, 2007           
(Date of earliest event reported)

LABORATORY CORPORATION OF
AMERICA HOLDINGS

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 8.01. Other Events

On February 28, 2007, Laboratory Corporation of America^® Holdings (LabCorp^®) (NYSE: LH), one of the world’s leading clinical laboratories, announced that it will no longer be a contracted laboratory provider for Aetna Inc. (NYSE: AET), effective July 1, 2007.

Exhibits

99.1 Press Release dated March 1, 2007

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Laboratory Corporation of America Holdings (Registrant)
Date: March 1, 2007	By:	/s/Bradford T. Smith
		Bradford T. Smith, Executive Vice President and Secretary

 

Exhibit 99.1

Laboratory Corporation of America® Holdings
358 South Main Street
Burlington, NC 27215
Telephone:(336) 584-5171

FOR IMMEDIATE RELEASE
Investor Contact: Scott Fleming - 336-436-4879
Media Contact: Pam Sherry - 336-436-4855
Shareholder Direct: (800)LAB-0401
Company Information: www.LabCorp.com

LABCORP^® NOTIFIED BY AETNA OF CONTRACT TERMINATION

Burlington, NC, March 1, 2007 — Laboratory Corporation of America^® Holdings (LabCorp^®) (NYSE: LH), one of the world’s leading clinical laboratories, today announced that it will no longer be a contracted laboratory provider for Aetna Inc. (NYSE: AET), effective July 1, 2007.

“We are disappointed with Aetna’s decision, but we are confident in our strategy for profitable growth,” stated David P. King, Chief Executive Officer of LabCorp. “Aetna has been a valued partner of ours for many years, and our recent expansion in their core Northeast markets means that we will be able to continue serving Aetna physicians and patients. We regret that we will do so as an out-of-network provider.”

LabCorp estimates that its 2007 earnings per share will be reduced by $0.04 to $0.12 primarily as a result of this contract termination.

“We remain focused on our strategic plan, a key component of which is expanding our managed care relationships and providing physicians and their patients with the nation’s most efficient, highest quality, and most advanced laboratory diagnostics,” said King.

About LabCorp^®
Laboratory Corporation of America^® Holdings, a S&P 500 company, is a pioneer in commercializing new diagnostic technologies and the first in its industry to embrace genomic testing. With annual revenues of $3.6 billion in 2006, over 25,000 employees nationwide, and more than 220,000 clients, LabCorp offers clinical assays ranging from routine blood analyses to HIV and genomic testing. LabCorp combines its expertise in innovative clinical testing technology with its Centers of Excellence: The Center for Molecular Biology and Pathology; National Genetics Institute, Inc.; ViroMed Laboratories, Inc.; The Center for Esoteric Testing; DIANON Systems, Inc.; US LABS; and Esoterix and its Colorado Coagulation, Endocrine Sciences, and Cytometry Associates laboratories. LabCorp clients include physicians, government agencies, managed care organizations, hospitals, clinical labs, and pharmaceutical companies. To learn more about our growing organization, visit our Web site at: www.LabCorp.com.

Each of the above forward-looking statements is subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payors. Actual results could differ materially from those suggested by these forward-looking statements. Further information on potential factors that could affect LabCorp’s financial results is included in the Company’s Form 10-K for the year ended December 31, 2006, and subsequent SEC filings.